{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:48:39Z","timestamp":1787615319986,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"\n Background:<\/jats:title>\n Melasma is a common acquired pigmentary skin disorder. Currently, there are various treatment options available but none is effective universally.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n \n Assess the role of Yuskin\n \u00ae<\/jats:sup>\n , a growth factor concentrate (GFC) therapy, a modified platelet rich plasma (PRP) technique for the treatment of melasma.\n <\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n Subjects of Fitzpatrick skin type IV\u2013V, of either gender, more than equal to 18 years of age, with a clinical diagnosis of melasma were enrolled in the study. Total three sessions of GFC monotherapy were given with one-month interval (day 0, day 30, and day 60) and follow up of subjects was done at day 90 for the final clinical assessment.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Out of 40 subjects enrolled, 30 subjects completed three GFC sessions and 26, completed day 90 follow-up. Statistically significant decrease in the mean mMASI scores was observed at all visits compared to baseline (\n P<\/jats:italic>\n < 0.005 for each visit). Totally, 66.7% of severe melasma subjects showed improvement to mild to moderate category. Significant improvement in mean mMASI score was seen in subjects who had mild to moderate melasma at baseline (\n P<\/jats:italic>\n < 0.05). Overall, aesthetic improvement was reported in 88.5% of subjects. Side effects reported were mild such as injection site pain, erythema, oedema and bruising, and resolved spontaneously within a few hours to few days of onset.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Significant improvement in melasma was observed with GFC monotherapy, which needs further confirmation in larger randomized controlled studies. Overall, it was well tolerated. Thus, GFC therapy can be a safe, effective, and new option in the armamentarium of melasma management.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/idoj.idoj_750_20","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T09:21:26Z","timestamp":1637054486000},"page":"549-554","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Prospective Study of Growth Factor Concentrate Therapy for Treatment of Melasma"],"prefix":"10.4103","volume":"12","author":[{"given":"Bindu","family":"Sthalekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan Y.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maulek","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20240828","first-page":"558","article-title":"Medical management of melasma: A review with consensus recommendations by Indian pigmentary expert group","volume":"62","author":"Sarkar","year":"2017","journal-title":"Indian J Dermatol"},{"key":"R2-8-20240828","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/archderm.1995.01690240119022","article-title":"Melasma: Etiologic and therapeutic considerations","volume":"131","author":"Grimes","year":"1995","journal-title":"Arch Dermatol"},{"key":"R3-8-20240828","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0190-9622(81)70071-9","article-title":"Melasma: A clinical, light microscopic, ultrastructural, and immunofluorescence study","volume":"4","author":"Sanchez","year":"1981","journal-title":"J Am Acad Dermatol"},{"key":"R4-8-20240828","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3390\/ijms17060824","article-title":"Heterogeneous pathology of melasma and its clinical implications","volume":"17","author":"Kwon","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R5-8-20240828","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2165\/00044011-199500102-00006","article-title":"Melasma in orientals","volume":"10","author":"Sivayathorn","year":"1995","journal-title":"Clin Drug Invest"},{"key":"R6-8-20240828","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4103\/0378-6323.79741","article-title":"Pattern and prevalence of physiological cutaneous changes in pregnancy: A study of 2000 antenatal women","volume":"77","author":"Rathore","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R7-8-20240828","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1468-3083.2009.03524.x","article-title":"Melasma in men: A clinical, aetiological and histological study","volume":"24","author":"Sarkar","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R8-8-20240828","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4103\/0019-5154.84722","article-title":"Melasma: A clinico-epidemiological study of 312 cases","volume":"56","author":"Achar","year":"2011","journal-title":"Indian J Dermatol"},{"key":"R9-8-20240828","first-page":"1","article-title":"Melasma and post inflammatory hyperpigmentation: Management update and expert opinion","volume":"21","author":"Sofen","year":"2016","journal-title":"Skin Therapy Lett"},{"key":"R10-8-20240828","doi-asserted-by":"crossref","first-page":"217","DOI":"10.12788\/j.sder.2018.049","article-title":"Melasma: Update on management","volume":"37","author":"Suggs","year":"2018","journal-title":"Semin Cutan Med Surg"},{"key":"R11-8-20240828","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13555-017-0194-1","article-title":"Melasma: An up-to-date comprehensive review","volume":"7","author":"Ogbechie-Godec","year":"2017","journal-title":"Dermatol Ther (Heidelb"},{"key":"R12-8-20240828","first-page":"718","article-title":"Therapeutic insights in melasma and hyperpigmentation management","volume":"18","author":"Huerth","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"R13-8-20240828","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000477353","article-title":"A review of platelet-rich plasma: History, biology, mechanism of action, and classification","volume":"4","author":"Alves","year":"2018","journal-title":"Skin Appendage Disord"},{"key":"R14-8-20240828","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ad.2013.12.021","article-title":"Platelet-rich plasma: Applications in dermatology","volume":"106","author":"Conde Montero","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"R15-8-20240828","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/jocd.12404","article-title":"Platelet-rich plasma, the ultimate secret for youthful skin elixir and hair growth triggering","volume":"17","author":"Elghblawi","year":"2018","journal-title":"J Cosmet Dermatol"},{"key":"R16-8-20240828","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/term.2832","article-title":"Platelet-rich plasma, a powerful tool in dermatology","volume":"13","author":"Merch\u00e1n","year":"2019","journal-title":"J Tissue Eng Regen Med"},{"key":"R17-8-20240828","first-page":"87","article-title":"Treatment of periorbital hyperpigmentation using platelet-rich plasma injections","volume":"3","author":"Al-Shami","year":"2014","journal-title":"Am J Dermatol Venereol"},{"key":"R18-8-20240828","doi-asserted-by":"crossref","first-page":"401","DOI":"10.5021\/ad.2014.26.3.401","article-title":"Regression of melasma with platelet-rich plasma treatment","volume":"26","author":"\u00c7ay\u0131rl\u0131","year":"2014","journal-title":"Ann Dermatol"},{"key":"R19-8-20240828","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/09546634.2018.1524821","article-title":"Platelet-rich plasma is a useful therapeutic option in melasma","volume":"30","author":"Hofny","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"R20-8-20240828","first-page":"1","article-title":"Response to intradermal autologous platelet rich plasma injection in refractory dermal melasma: Report of two cases","volume":"18","author":"Yew","year":"2015","journal-title":"J Health Transl Med"},{"key":"R22-8-20240828","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaad.2009.10.051","article-title":"Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method","volume":"64","author":"Pandya","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R23-8-20240828","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41702-017-0019-y","article-title":"Efficacy of Skinfill plus filler in the management of facial aging: A multicenter, post-marketing clinical study","volume":"2","author":"Savoia","year":"2018","journal-title":"Biomed Dermatol"},{"key":"R24-8-20240828","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/2349-5847.208298","article-title":"Melasma: Its impact on quality of life","volume":"4","author":"Morgaonkar","year":"2017","journal-title":"Pigment Int"},{"key":"R25-8-20240828","first-page":"1482","article-title":"Transforming growth factor-\u03b21 decreases melanin synthesis via delayed extracellular signal-regulated kinase activation","volume":"36","author":"Kim","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"R26-8-20240828","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.molcel.2008.11.002","article-title":"Inhibition of PAX3 by TGF-\u03b2 modulates melanocyte viability","volume":"32","author":"Yang","year":"2008","journal-title":"Mol Cell"},{"key":"R27-8-20240828","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1600-0749.2006.00334.x","article-title":"Hypopigmenting agents: An updated review on biological, chemical and clinical aspects","volume":"19","author":"Solano","year":"2006","journal-title":"Pigment Cell Res"},{"key":"R28-8-20240828","first-page":"355","article-title":"Efficacy of platelet-rich plasma in the treatment of melasma: A pilot study","volume":"28","author":"Faiz","year":"2018","journal-title":"J Pak Assoc Dermatol"},{"key":"R29-8-20240828","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/jocd.13157","article-title":"Platelet-rich plasma treatment for melasma: A pilot study","volume":"19","author":"Sirithanabadeekul","year":"2020","journal-title":"J Cosmet Dermatol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.IDOJ_750_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:12:45Z","timestamp":1787166765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.IDOJ_750_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_750_20","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}